Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

SARS-CoV-2-Neutralizing Monoclonal COVID-19 Antibody DZIF-10c by Infusion

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04631666
Recruitment Status : Recruiting
First Posted : November 17, 2020
Last Update Posted : March 22, 2021
Sponsor:
Collaborators:
ZKS Köln
Boehringer Ingelheim
Information provided by (Responsible Party):
Florian Klein, University of Cologne

Brief Summary:
This is the first-in-human phase 1/2a trial of the intravenous administration of the SARS-CoV-2-neutralizing monoclonal antibody DZIF-10c in healthy volunteers and SARS-CoV-2-infected individuals. It will evaluate the safety, pharmacokinetic profile, immunogenicity, and antiviral activity of DZIF-10c.

Condition or disease Intervention/treatment Phase
SARS-CoV-2 Infection Biological: DZIF-10c Other: Placebo Phase 1 Phase 2

Detailed Description:
The phase 1 component of this trial consists of a single intravenous infusion open-label dose-escalation phase (Groups 1A-1D and Group 2C). Subsequently, the highest tested and tolerated dose will be administered to an expansion cohort of SARS-CoV-2-infected individuals (Group 2D). In this randomized and blinded group, participants will receive DZIF-10c or placebo by intravenous infusion.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 57 participants
Allocation: Randomized
Intervention Model: Sequential Assignment
Intervention Model Description:

This study consists of an open-label dose escalation phase in healthy volunteers (Groups 1A-1C) and an additional open-label lead-in phase in SARS-CoV-2-infected individuals (Group 2C).

After completion of the dose escalation phase, SARS-CoV-2-infected individuals will be enrolled into a randomized placebo-controlled expansion cohort (Group 2D).

An additional higher dose cohort may be included for healthy volunteers (Group 1D).

Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: A Phase 1/2a Trial of the Intravenous Administration of the SARS-CoV-2-Neutralizing Monoclonal Antibody DZIF-10c in SARS-CoV-2-Infected and -Uninfected Individuals
Actual Study Start Date : December 8, 2020
Estimated Primary Completion Date : July 31, 2021
Estimated Study Completion Date : July 31, 2021

Arm Intervention/treatment
Experimental: Group 1A (uninfected) - 2.5 mg/kg
SARS-CoV-2-uninfected volunteers will receive a single intravenous infusion of DZIF-10c at a dose of 2.5 mg/kg
Biological: DZIF-10c
SARS-CoV-2-neutralizing monoclonal antibody DZIF-10c by intravenous infusion

Experimental: Group 1B (uninfected) - 10 mg/kg
SARS-CoV-2-uninfected volunteers will receive a single intravenous infusion of DZIF-10c at a dose of 10 mg/kg
Biological: DZIF-10c
SARS-CoV-2-neutralizing monoclonal antibody DZIF-10c by intravenous infusion

Experimental: Group 1C (uninfected) - 40 mg/kg
SARS-CoV-2-uninfected volunteers will receive a single intravenous infusion of DZIF-10c at a dose of 40 mg/kg
Biological: DZIF-10c
SARS-CoV-2-neutralizing monoclonal antibody DZIF-10c by intravenous infusion

Experimental: Group 1D (uninfected) - high dose
SARS-CoV-2-uninfected volunteers will receive a single intravenous infusion of DZIF-10c at a dose higher than 40 mg/kg
Biological: DZIF-10c
SARS-CoV-2-neutralizing monoclonal antibody DZIF-10c by intravenous infusion

Experimental: Group 2C (infected) - 40 mg/kg
SARS-CoV-2-infected volunteers will receive a single intravenous infusion of DZIF-10c at a dose of 40 mg/kg
Biological: DZIF-10c
SARS-CoV-2-neutralizing monoclonal antibody DZIF-10c by intravenous infusion

Experimental: Group 2D (infected) - 40 mg/kg
SARS-CoV-2-infected volunteers will be randomized 2:1 to receive an intravenous infusion of DZIF-10c at a dose of 40 mg/kg or placebo
Biological: DZIF-10c
SARS-CoV-2-neutralizing monoclonal antibody DZIF-10c by intravenous infusion

Other: Placebo
Intravenous infusion of sterile normal saline (NaCl 0.9%) as placebo




Primary Outcome Measures :
  1. Rate of Adverse Events after a single DZIF-10c infusion [Safety and Tolerability] [ Time Frame: 3 months ]
    Primary target variables are (S)AEs and Adverse Events of Special Interest (AESIs)


Secondary Outcome Measures :
  1. Pharmacokinetic profile of DZIF-10c [ Time Frame: 3 months ]
    Elimination half-life (t1/2) of DZIF-10c

  2. Pharmacokinetic profile of DZIF-10c [ Time Frame: 3 months ]
    Peak serum concentration (Cmax) of DZIF-10c

  3. Pharmacokinetic profile of DZIF-10c [ Time Frame: 3 months ]
    Area under the curve (AUC)

  4. Pharmacokinetic profile of DZIF-10c [ Time Frame: 3 months ]
    Clearance (CL/F) of DZIF-10c

  5. Pharmacokinetic profile of DZIF-10c [ Time Frame: 3 months ]
    Volume of distribution (Vz/F) of DZIF-10c

  6. Development of anti-drug antibodies [ Time Frame: 3 months ]
    Frequency of the development of anti-drug antibodies targeting DZIF-10c

  7. Development of anti-drug antibodies [ Time Frame: 3 months ]
    Magnitude of the development of anti-drug antibodies targeting DZIF-10c

  8. Change in viral load in nasopharyngeal swabs after DZIF-10c administration [ Time Frame: 28 days ]
    Change in SARS-CoV-2 RNA from baseline in nasopharyngeal swabs as determined by qRT-pCR



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

Groups 1A-1D

  • Age 18-65.
  • SARS-CoV-2-RNA negative naso- or oropharyngeal swab obtained within 3 calendar days before study drug administration by NAAT (e.g., qRT-PCR).
  • Non-reactivity of serum antibodies (IgG; and IgA and/or IgM when tested) against SARS-CoV-2 by serological assay at screening.

Groups 2C-2D

  • Age 18-70.
  • SARS-CoV-2-RNA positive naso- or oropharyngeal swab obtained within 3 calendar days before study drug administration by NAAT (e.g., qRT-PCR).
  • Onset of COVID-19 symptoms (e.g., sore throat, cough, fever, chills, fatigue, dys- or anosmia, dys- or ageusia, headache, muscle pain, gastrointestinal symptoms) within 7 days prior to study drug administration or Non-reactivity of serum or plasma antibodies (IgG; and IgA and/or IgM when tested) against SARS-CoV-2 by serological assay at screening.
  • Disease severity score 1-4 as defined by the WHO Clinical Progression Scale (WHO, Lancet Inf Dis 2020).

Exclusion Criteria (all groups):

  • Known hypersensitivity to any constituent of the investigational medicinal product.
  • Hepatitis B infection indicated by detectable HBsAg (Hepatitis B surface antigen) in blood.
  • Detectable antibodies against hepatitis C virus in blood unless active hepatitis C is ruled out by negative HCV-RNA.
  • HIV infection indicated by detectable HIV antigen and/or HIV antibodies in blood.
  • Neutrophil count ≤1,000 cells/µl
  • Hemoglobin ≤10 g/dl
  • Platelet count ≤100,000 cells/µl
  • ALT ≥2.0 x ULN
  • AST ≥2.0 x ULN
  • Total bilirubin ≥1.5 ULN
  • eGFR <60 ml/min/1.73m2
  • Pregnancy or lactation.
  • Any vaccination within 14 days prior to DZIF-10c administration.
  • Receipt of any SARS-CoV-2 vaccine or SARS-CoV-2 monoclonal antibody in the past.
  • Diagnosis of bronchial asthma or history of bronchial hyperresponsiveness, COPD, pulmonary fibrosis, or other chronic lung diseases.
  • Any chronic or clinically significant medical condition that in the opinion of investigator would jeopardize the safety or rights of the volunteer.
  • History of systemic corticosteroids, immunosuppressive anti-cancer, or other medications considered significant by the trial physician within the last 6 months (a single administration of systemic corticosteroids within ≤6 months and ≥4 weeks of enrollment is acceptable).
  • Participation in another clinical trial of an investigational medicinal product within the past 12 weeks or expected participation during this study.
  • Dependency on the principal investigator or study staff; or site personnel directly affiliated with this trial.
  • Legally incapacitated individuals
  • Individuals held in an institution by legal or official order
  • If engaging in sexual activity that could result in pregnancy, inability or unwillingness to comply with the requirements for highly effective contraception

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04631666


Contacts
Layout table for location contacts
Contact: Henning Gruell, MD +49-221-478-96973 henning.gruell@uk-koeln.de
Contact: Florian Klein, MD +49-221-478-85801 florian.klein@uk-koeln.de

Locations
Layout table for location information
Germany
University Hospital Cologne Recruiting
Cologne, NRW, Germany, 50937
Contact: Gerd Fätkenheuer, MD    +49-221-478-38374    gerd.faetkenheuer@uk-koeln.de   
Contact: Jakob Malin, MD    +49-221-478-38374    jakob.malin@uk-koeln.de   
Principal Investigator: Gerd Fätkenheuer, MD         
Sub-Investigator: Jakob Malin, MD         
Sponsors and Collaborators
University of Cologne
ZKS Köln
Boehringer Ingelheim
Investigators
Layout table for investigator information
Principal Investigator: Gerd Fätkenheuer, MD University of Cologne
Publications:
Layout table for additonal information
Responsible Party: Florian Klein, Investigator, University of Cologne
ClinicalTrials.gov Identifier: NCT04631666    
Other Study ID Numbers: Uni-Koeln-4288
First Posted: November 17, 2020    Key Record Dates
Last Update Posted: March 22, 2021
Last Verified: March 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Florian Klein, University of Cologne:
SARS-CoV-2
Covid-19
Infusion
Monoclonal Antibody